Persistence and risk factors of high-risk human papillomavirus infection among HIV positive and HIV negative tanzanian women: a cohort study

被引:3
|
作者
Swai, Patricia [1 ]
Rasch, Vibeke [2 ,3 ]
Linde, Ditte S. [2 ,3 ]
Mchome, Bariki [1 ]
Manongi, Rachel [1 ]
Wu, Chun Sen [2 ]
Waldstrom, Marianne [4 ]
Iftner, Thomas [5 ]
Mwaiselage, Julius [6 ]
Kjaer, Susanne K. [7 ,8 ]
机构
[1] Kilimanjaro Christian Med Ctr, Moshi 3060, Tanzania
[2] Univ Southern Denmark, Odense, Denmark
[3] Odense Univ Hosp, Dept Gynaecol & Obstet, Odense, Denmark
[4] Lillebaelt Hosp, Dept Pathol, Vejle, Denmark
[5] Univ Hosp Tubingen, Inst Med Virol, Tubingen, Germany
[6] Ocean Rd Canc Inst, Dar Es Salaam, Tanzania
[7] Danish Canc Soc Res Ctr, Unit Virus Lifestyle & Genes, Copenhagen, Denmark
[8] Univ Copenhagen, Rigshosp, Dept Gynecol, Copenhagen, Denmark
关键词
HR HPV; Persistence; Risk factors; HIV status; Tanzania; HPV INFECTION;
D O I
10.1186/s13027-022-00442-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background High-risk (HR) human papillomavirus (HPV) persistence is the most important risk factor for cervical cancer. We have assessed the type-specific HR HPV persistence among HIV positive and HIV negative Tanzanian women and factors associated with HR HPV persistence. Methods In a cohort study including 4080 Tanzanian women, 3074 attended follow-up examination (up to 32 months after enrollment). Cervical samples were obtained for liquid-based cytology and HPV DNA testing using Hybrid Capture 2 and Inno-Lipa Extra II. Information on lifestyle factors was collected through a personal interview. The probability of HR HPV persistence at a given time point since enrollment was estimated non-parametrically using the EMICM algorithm. Results Among the 462 women HR HPV positive at enrollment, 158 had at least one identical type detected at follow-up. The probability of persistence at 18 months after enrollment was 34.2 (95% CI 29.0-39.4). Stratifying by HIV status, the persistence probability was 42.9% (95% CI 33.5-51.9) among HIV positive, and 28.0% (95% CI 22.1-34.2) among HIV negative. Overall, HR HPV persistence was most common for HPV58, 35, 16, 31, and 52. Among HIV positive women it was HPV45, and HPV16, followed by HPV58 and HPV18, and among HIV negative women it was HPV31, HPV33 and HPV58. Risk factors associated with persistence of HR HPV were older age, longer interval between enrollment and follow-up, binge drinking, and HIV status. Conclusions HR HPV persistence was common in Tanzania, and most common among HIV positive women. Overall, persistence was most frequent for HPV 58, 35, 16, 31 and 52. The nonavalent HPV vaccine should be considered.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Continuity of medical care and risk of incarceration in HIV-positive and high-risk HIV-negative women
    Sheu, M
    Hogan, J
    Allsworth, J
    Stein, M
    Vlahov, D
    Schoenbaum, EE
    Schuman, P
    Gardner, L
    Flanigan, T
    [J]. JOURNAL OF WOMENS HEALTH & GENDER-BASED MEDICINE, 2002, 11 (08): : 743 - 750
  • [42] High Risk Human Papillomavirus Persistence Among HIV-infected Young Women in South Africa
    Adler, David
    Wallace, Melissa
    Bennie, Thola
    Abar, Beau
    Sadeghi, Rokhsanna
    Meiring, Tracy
    Williamson, Anna-Lise
    Bekker, Linda-Gail
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2015, 33 : 219 - 221
  • [43] Screening of human papillomavirus, cervical cytological abnormalities and associated risk factors in HIV positive and HIV-negative women in Rwanda
    Manzi, O. M.
    [J]. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2017, 22 : 104 - 104
  • [44] HIV-1, HIV-2, human papillomavirus infection and cervical neoplasia in high-risk African women
    Langley, CL
    BengaDe, E
    Critchlow, CW
    Ndoye, I
    MbengueLy, MD
    Kuypers, J
    WotoGaye, G
    Mboup, S
    Bergeron, C
    Holmes, KK
    Kiviat, NB
    [J]. AIDS, 1996, 10 (04) : 413 - 417
  • [45] Vaginal Bacteria and Risk of Incident and Persistent Infection With High-Risk Subtypes of Human Papillomavirus: A Cohort Study Among Kenyan Women
    Carter, Kayla A.
    Srinivasan, Sujatha
    Fiedler, Tina L.
    Anzala, Omu
    Kimani, Joshua
    Mochache, Vernon
    Wallis, Jacqueline M.
    Fredricks, David N.
    McClelland, R. Scott
    Balkus, Jennifer E.
    [J]. SEXUALLY TRANSMITTED DISEASES, 2021, 48 (07) : 499 - 507
  • [46] Twelve-Year Trend in the Prevalence of High-Risk Human Papillomavirus Infection Among Rwandan Women Living With HIV
    Murenzi, Gad
    Kanyabwisha, Faustin
    Murangwa, Anthere
    Kubwimana, Gallican
    Mutesa, Leon
    Burk, Robert D.
    Anastos, Kathryn
    Castle, Philip E.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2020, 222 (01): : 74 - 81
  • [47] High-risk human papillomavirus genotypes distribution in a cohort of HIV-positive women living in Europe: epidemiological implication for vaccination against human papillomavirus
    Konopnicki, Deborah
    Manigart, Yannick
    Gilles, Christine
    Barlow, Patricia
    De Marchin, Jerome
    Feoli, Francesco
    Delforge, Marc
    Clumeck, Nathan
    De Wit, Stephane
    [J]. AIDS, 2016, 30 (03) : 425 - 433
  • [48] Human papillomavirus prevalence and risk factors among HIV-negative and HIV-positive women residing in rural Eastern Cape, South Africa
    Taku, Ongeziwe
    Businge, Charles B.
    Mdaka, Mana L.
    Phohlo, Keletso
    Basera, Wisdom
    Garcia-Jardon, Mirta
    Meiring, Tracy L.
    Gyllensten, Ulf
    Williamson, Anna-Lise
    Mbulawa, Zizipho Z. A.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 95 : 176 - 182
  • [49] Prevalence of risk factors associated with human papillomavirus infection in women living with HIV
    Hankins, C
    Coutlée, F
    Lapointe, N
    Simard, P
    Tran, T
    Samson, J
    Hum, L
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 1999, 160 (02) : 185 - 191
  • [50] Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women
    Viscidi, RP
    Snyder, B
    Cu-Uvin, S
    Hogan, JW
    Clayman, B
    Klein, RS
    Sobel, J
    Shah, KV
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (01) : 283 - 288